Option chain shows key data for NKGen Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NKGen Biotech.

NKGen Biotech (OTC:NKGN) Stock, Option Chain

NKGen Biotech

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

AppLovin Corp APP

ASPN

ATAI

AVGR

BROS

CEVA

FSLY

HOOD

LPRO

MGOL

MYNA

NKGN

OMGA

PRPH

RDDT

SLSR

TIVC

TWIN

Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

Spirit_Airlines-Wikimedia Commons

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGFY

APVO

BIVI

EFSH

GNPX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

JDZG

LGMK

MTEM

PHIO

SAVE

SHLS

TNON

VSEE

VSME

VTAK

XPON

ZPTA

Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket

Wall Street

Equities

Eurozone

Commodities

Intraday Update

DRUG

NFLX

NUZE

ORGS

SOBR

Dow Falls Over 100 Points; Netflix Posts Upbeat Results

NKGen Biotech Inc

Press Releases

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit

Health Care

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations

Comments

NKGen Biotech

NKGen Biotech (NKGN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell